Nvidia’s Israeli research operation is expanding its work on artificial intelligence for medicine and science, connecting its computing expertise with efforts to understand genetic disease, develop medicines and design new materials. Its Applied AI Architecture group is recruiting researchers, while institutional announcements already document its involvement in a major U.S.-Israeli genomics partnership. (nvidia.wd5.myworkdayjobs.com)
The latest expansion details emerged Sept. 23, when Calcalist reported that Nvidia plans to add dozens of specialists over the coming year to a team currently numbering several researchers. Those staffing targets remain attributed to Calcalist; the primary announcements reviewed do not independently confirm the planned headcount. (Ctech)
For hospitals and drug developers, the potential benefit is help tackling research problems that require enormous amounts of data and computing power. For Israeli researchers, the reported recruitment would create additional opportunities to work at the intersection of technology and scientific discovery.
Calcalist reports that the group operates within Nvidia’s global chief technology office, headed by Michael Kagan, and is led by Dr. Nati Daniel. Its work focuses on scientific concepts that could eventually become part of Nvidia’s technology, rather than an immediate commercial product. (Ctech)
The timing requires an important distinction: although the expansion is newly reported, the group was publicly identified in a Mount Sinai announcement in November 2025. Describing it as having first been established this week would go beyond the available evidence. (Mount Sinai – New York)
One of its clearest connections to American healthcare runs through New York.
On Nov. 18, 2025, ARC Innovation at Sheba Medical Center and the Icahn School of Medicine at Mount Sinai announced a three-year collaboration with Nvidia to apply AI to genomic research. That announcement identified Daniel and Dr. Yoli Shavit with Nvidia’s Applied AI Architecture group.
The institutions said Sheba and Mount Sinai would contribute genetic datasets and clinical expertise, while Nvidia would provide computing architecture, software and scientific support. Researchers aim to identify patterns linking genetic differences with disease risk and treatment response.
In everyday terms, the ambition is to help scientists understand how a person’s genetic makeup influences illness and how that knowledge might guide treatment. The announcement describes a research program, however, rather than a diagnostic service already available to patients. (Mount Sinai – New York)
Drug discovery provides another U.S. connection. Calcalist reports that the Israeli group participates in Nvidia’s broader collaboration with Eli Lilly. (Ctech)
Nvidia and Lilly announced Jan. 12 that they would jointly invest up to $1 billion over five years in talent, infrastructure and computing for an AI research laboratory in the San Francisco Bay Area. That commitment covers the wider collaboration; it is not a disclosed budget for the Israeli team.
The companies’ approach connects computer-based research with physical laboratory experiments. Scientists would use AI to explore possible molecules, test promising candidates and feed experimental results back into the models.
For pharmaceutical businesses, the intended payoff is a more productive research process: identifying useful candidates earlier and learning faster from experiments. The announcement does not establish that the collaboration has already delivered an approved medicine, lower prescription prices or a measured reduction in development costs. (NVIDIA Newsroom)
Materials science broadens the effort beyond healthcare. Calcalist identifies the team as participating in GENMAT, an international project developing AI tools for materials research. (Ctech)
European Commission records show that GENMAT began June 1, 2026, runs through May 31, 2029, and carries an EU contribution of approximately €5.95 million. Its objective is to connect information about chemistry, manufacturing and material performance so industry can develop useful materials faster and at lower cost. Those are project goals, and the funding covers the consortium rather than Nvidia’s Israeli group alone. (European Commission)
The next tests are concrete: whether the reported hiring takes place, what the partnerships publish and whether their research produces tools that work reliably beyond experimental settings. For patients and businesses, those results will determine how much of the scientific ambition becomes practical value.
JBizNews Desk | Tel Aviv
© JBizNews.com All Rights Reserved. Reproduction or distribution without written permission is prohibited.
